X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gesynta Pharma’s first-in-class drug candidate GS-248 provides a combination of anti-inflammatory and vasodilatory effects by potently and selectively inhibiting microsomal prostaglandin E synthase-1 (mPGES-1).
Lead Product(s): GS-248
Therapeutic Area: Immunology Product Name: GS-248
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
The investment enables Gesynta to fund continued development of lead candidate GS-248 in systemic sclerosis patients.
Lead Product(s): GS-248
Therapeutic Area: Dermatology Product Name: GS-248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hadean Ventures
Deal Size: $21.1 million Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2020
Details:
The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.
Lead Product(s): BI1029539
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
